Email: cspc@cspc.cn
Email: cspc@cspc.cn
July 27, 2022
Mitoxantrone hydrochloride liposome for injection (10ml:10mg), our key innovative product, has been launched successfully on January 11. This product is a self-developed anti-tumor nano-drug of CSPC as well as the first mitoxantrone nano-drug launched in the world, with its patent for invention granted in more than 10 countries and regions, such as China, the US, Europe and Japan. The product adopts a unique drug loading and releasing technique to ensure that the nanoparticles can effectively converge in the tumors and reasonably release the drug after the drug is administered. In this case, the bioavailability of the drug in the tumors can be enhanced, and the efficacy and safety can be significantly improved. Satisfactory clinical data has been obtained on the first indication PTCL, and multiple clinical trials on solid tumors and large tumors are underway, showing a considerable market potential.
